shRNA medicine capable of specifically inhibiting macrophage migration inhibition factor (MIF) and application thereof

A specific and species-specific technology, applied in the field of shRNA drugs that specifically inhibit macrophage migration inhibitory factor, can solve the problem of not finding shRNA therapeutic drugs, achieve important application value, relieve growth and lung metastasis symptoms, and have a significant curative effect. Effect

Inactive Publication Date: 2017-09-15
NANJING UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In recent years, RNA interference has made progress in the treatment of some tumors and viral infectious diseases, but no effective shRNA has been found as a therapeutic drug for osteosarcoma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • shRNA medicine capable of specifically inhibiting macrophage migration inhibition factor (MIF) and application thereof
  • shRNA medicine capable of specifically inhibiting macrophage migration inhibition factor (MIF) and application thereof
  • shRNA medicine capable of specifically inhibiting macrophage migration inhibition factor (MIF) and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0019] The present invention will be further described below in conjunction with specific examples. The examples of the present invention are only used to explain the present invention, and are not meant to limit the protection scope of the present invention.

[0020] The experimental methods used in the following examples are conventional methods unless otherwise specified.

[0021] The materials and reagents used in the following examples can be obtained from commercial sources unless otherwise specified.

[0022] 1. Samples and sources of materials

[0023] Sixty cases of intraoperative osteosarcoma tissue samples and corresponding paracancerous tissue samples were collected from Nanjing General Hospital of Nanjing Military Region from 2008 to 2012. Among them, 40 were males and 20 were females. The clinical staging of osteosarcoma was based on the Enneking staging method: 58 cases of stage IIB and 2 cases of stage III; histological classification was based on the Dahlin ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention specifically relates to a shRNA medicine capable of specifically inhibiting a MIF and application thereof, belonging to the technical field of biological medicine. The shRNA medicine capable of specifically inhibiting the MIF is a nanometer compound composed of a nucleic acid drug capable of inhibiting expression of the MIF and a cationic polymer polyethyleneimine (PEI). Detection results of enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry (IHC) show that the MIF substantially increases in the serums and tissue of patients with osteosarcomas. Further research shows that the expression of the MIF in tissue is related to the survival rate of the patients with osteosarcomas. shRNA expression plasmids capable of inhibiting the expression of the MIF can substantially inhibit propagation of osteosarcoma cells; and the shRNA medicine can obviously inhibit the growth of tumors in mouse osteosarcoma models and the pulmonary metastasis extent of the tumors. The invention provides a novel therapeutic for clinical treatment of osteosarcomas.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to a shRNA drug for specifically inhibiting macrophage migration inhibitory factor (MIF) and an application thereof. Background technique [0002] Osteosarcoma is a common primary bone tumor that mostly occurs in adolescents and presents as a mass in the legs, pain, and movement disorders. The incidence of osteosarcoma is very low, but the degree of malignancy is high, and it is prone to lung metastasis, which seriously endangers the health of young people. For newly diagnosed patients without metastases, the 5-year survival rate is between 40% and 75%. 20% of patients have lung metastases when they are first diagnosed, and their 5-year survival rate is less than 30%. [0003] The diagnostic methods of osteosarcoma mainly include tomography (CT) and nuclear magnetic resonance (MRI) radiological examination and pathological evaluation through tissue sections. When ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7105A61K47/34A61K48/00A61P35/00
CPCA61K31/7105A61K9/0019A61K47/34
Inventor 陈江宁张峻峰王晨李文涛李明月黄振赵建宁周幸
Owner NANJING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap